Premium
T‐cell receptor antibodies in the immunohistochemical studies of normal and malignant lymphoid cells
Author(s) -
Chan Wing C.,
Borowitz Michael J.,
Hammami Amir,
Wu Y. J.,
Ip Stephen J.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19881115)62:10<2118::aid-cncr2820621009>3.0.co;2-4
Subject(s) - antibody , cd3 , pathology , immunohistochemistry , antigen , biology , medicine , microbiology and biotechnology , immunology , cd8
Three anti‐T Cell receptor (TCR) antibodies, BF 1 , BF 2 , and WT31 were studied for their specificity and usefulness as immunohistochemical reagents. These antibodies were all satisfactory in the staining of normal peripheral lymphoid tissues and cortical thymic lymphocytes were reactive with BF 1 and BF 2 but not with WT31. Hassall's corpuscles in two of three thymuses studied reacted with all three antibodies. BF 1 was superior to the other two antibodies, especially for lymphoid cells in cytospin preparations. Fifty‐five lymphomas, 24 nonlymphoid malignancies, seven established cell lines, and five cases of large granular lymphocyte (LGL) proliferation with neutropenia were studied. The majority of non‐T‐cell lesions did not react with the antibodies. An occasional case showed weak reactivity which could be easily distinguished from the usual strong reaction with T‐cells. Tumor cells from over 90% of snap frozen peripheral T‐cell lymphomas reacted with BF 1 and BF 2 . BF 1 was the preferred antibody since it gave a stronger and more consistent reaction. It was also the antibody of choice in identifying T‐lymphoblastic lymphomas. Michel's solution fixed tissue showed markedly diminished or absent reactivity with BF 2 and WT31, but BF 1 reactivity was less affected. Some unusual T‐cell phenotypes, with respect to the pattern of expression of BF 1 antigen and CD3, were observed. BF 1 and anti‐CD3, in combination, would be useful in identifying T‐cell lesions with aberrant or unusual TCR‐CD3 phenotypes.